ReviewFrontiers in immunology2019
Exploiting Human NK Cells in Tumor Therapy.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Trial
- Effects of sevoflurane on natural killer cell-induced apoptosis of malignant tumour cells: an in vitro laboratory study.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2026Article
- Optimizing activation and culture conditions for the production of cord blood-derived CAR-T and natural killer cells.British journal of haematology · 2025Article
- Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy.Immunotherapy · 2025Review
- Diverse Subsets of γδT Cells and Their Specific Functions Across Liver Diseases.International journal of molecular sciences · 2025Review
- Cell therapy in pediatric blood diseases.Frontiers in medicine · 2025Review
- Safety but limited efficacy of donor lymphocyte infusion for post-transplantation cyclophosphamide-treated patients.Bone marrow transplantation · 2024Article
- Review
- Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy.Pharmaceutics · 2024Review
- Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.Acta pharmaceutica Sinica. B · 2024Review
- CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.Journal of experimental & clinical cancer research : CR · 2024Article
- Review
- NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.International journal of biological sciences · 2024Article
- Exploiting autophagy balance in T and NK cells as a new strategy to implement adoptive cell therapies.Molecular cancer · 2023Review
- Emerging frontiers in immuno- and gene therapy for cancer.Cytotherapy · 2023Review
- Tumor-infiltrating lymphocytes and macrophages as a significant prognostic factor in biliary tract cancer.PloS one · 2023Article
- Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.Frontiers in immunology · 2023Review
- Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.Pharmacology & therapeutics · 2022Review
- Natural killer cells: a promising immunotherapy for cancer.Journal of translational medicine · 2022Review
- Cell-in-cell structure mediates in-cell killing suppressed by CD44.Cell discovery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NK cells play an important role in the innate defenses against tumor growth and metastases. Human NK cell activation and function are regulated by an array of HLA class I-specific inhibitory receptors and activating receptors recognizing ligands expressed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.